THE TEAM

“A combination of young ambitious entrepreneurs, renowned scientific leaders and seasoned business experts”.

Digvijay Gahtory
PhD

Chief Executive Officer

Dr. Digvijay Gahtory is a young and ambitious  entrepreneur with a solid track record in biotech consulting, raising over €15M in non-dilutive funding for biotech companies. He has obtained a doctorate (cum laude) in organic chemistry from Wageningen University and is a registered pharmacist. He is passionate about making a meaningful impact on the world.

Linkedin

Maurits van den Nieuwboer PhD

Chief Operational Officer

Dr. Maurits van den Nieuwboer has been a strategic consultant for the biopharma field, having successfully supported multiple innovative SMEs and obtained over €25M in financing. He is trained as a biomedical scientist and obtained his PhD at the VU University in innovation and entrepreneurship. He is driven to bring innovation from bench to bedside.

Linkedin

Prof. Ger
Strous PhD

Chief Scientific Officer

Prof. Ger Strous, the CSO of BIMINI Biotech, is a professor emeritus at UMC Utrecht who has performed pioneering research in the field of the GH/IGF-1 axis for the past 40 years. Since 1990, he has studied the regulation of cytokine receptors (the GH receptor), and is the main inventor of BIMINI’s technology. Prof. Strous is key in driving the scientific progress of the company.

Linkedin

SCIENTIFIC AND BUSINESS ADVISORS

Henk Viëtor MD
PhD

ADVISOR BUSINESS DEVELOPMENT

Dr. Henk Viëtor is a medical doctor, scientist by training and a serial biotech entrepreneur. He is co-founder of more than 20 (Life Sciences) spin–off companies, including Drug Discovery Factory, Catalyze, Julius Clinical, Skyline Diagnostics and DC4U. 

Linkedin

Judith Smit
PhD

ADVISOR Strategy and finance

Dr. Judith Smit is entrepreneur and managing partner at FFUND. She is specialized in strategic business development and financing for start-up and scale-up companies. She obtained her PhD in molecular biology at The Netherlands Cancer Institute.

Linkedin

Peter
Maas

ADVISOR Medicinal Chemistry

Peter Maas is a medicinal chemistry expert and manager of lead development at Specs with over 30 years of industrial experience. He actively supported drug development programmes of various bio-techs including Oncodrone, Qiadis.

Linkedin

Prof. Marc
Peeters PhD

ADVISOR CLINICAL DEVELOPMENT

Prof. Marc Peeters is head of the oncology department at the Antwerp University Hospital (UZA) and coordinator of the Multidisciplinary Oncology Center Antwerp. Previously, he was the coordinator of the Digestive Oncology Unit (Ghent).

Linkedin

Carine van den Brink

ADVISOR Legal

Carine is a lawyer with a medical background and in-depth knowledge of the biotech and technology markets. She has an international transaction practice with focus on intellectual property licensing and M&A. She is partner at Axon Lawyers.

Linkedin

Ir. Jan Mol
PhD

ADVISOR Pre-clinical r&D

Dr. Ir. Jan Mol studied Molecular Sciences at Wageningen University and received his PhD in medicine. At Utrecht University, he is  principal investigator in the field of endocrinology, oncology and functional genomics of companion animals

Linkedin

Johan
Tijhuis PhD

ADVISOR Drug development

Johan is the CEO at Specs compound handling in Zoetermeer. It  is the world’s leading provider of compound management services and supplier of research compounds to the Life Science industry. Johan has a PhD in organic chemistry

Linkedin

Our Story

BIMINI Biotech is an innovative spin-off of the Utrecht University Medical center (UMCU) in the Netherlands.

The company was established at the end of 2019, based on the breakthrough research performed by the group of Prof. Ger Strous, after showing promising effects in several cancer types with our lead compound BM001. The company is currently in its pre-clinical stage, aiming to bring the compound towards the clinic.

Get connected

We are always open to discuss potential collaborations to bring innovative oncology therapeutics closer to the patient. Please feel free to contact us.  

Let's talk